Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 2/2013

01-04-2013 | Gastrointestinal Cancers (BG Czito, Section Editor)

The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer

Authors: Thierry Conroy, Céline Gavoille, Emmanuelle Samalin, Marc Ychou, Michel Ducreux

Published in: Current Oncology Reports | Issue 2/2013

Login to get access

Abstract

In 2010, the FOLFIRINOX regimen (bolus and infusional 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) emerged as a new option in patients with metastatic pancreatic cancer and a good performance status. However, at that time, some doubts were raised regarding safety issues. Similarly, no data on FOLFIRINOX were published in patients with unresectable/locally advanced or borderline resectable pancreatic cancer. This article presents the available experience with FOLFIRINOX outside clinical trials in metastatic and locally advanced pancreatic cancer patients. The safety of the regimen in patients with biliary stents and in previously treated patients is also described. FOLFIRINOX usage in clinical practice, including modification of the regimen (omission of bolus 5-fluorouracil; FOLFOXIRI regimen), is also presented. These data suggest that a phase III randomized study is warranted to further explore the role of FOLFIRINOX in locally advanced pancreatic cancer.
Literature
1.
2.
3.
Sant M, Allemani C, Santaquilani M, et al. EUROCARE Working Group. EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. Eur J Cancer. 2009;45:931–91.PubMedCrossRef
4.
Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer. 1995;76:1671–7.PubMedCrossRef
5.
Lefebvre AC, Maurel J, Boutreux S, et al. Pancreatic cancer: incidence, treatment and survival trends – 1175 cases in Calvados (France) from 1978 to 2002. Gastroenterol Clin Biol. 2009;33:1045–51.PubMedCrossRef
6.
Burris 3rd AH, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.PubMed
7.
Conroy T, Mitry E. Chimiothérapie de l’adénocarcinome du pancréas métastatique: défis et espoirs. Bull Cancer. 2011;98:1438–46.
8.
•• Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513–8. The gemcitabine–capecitabine combination resulted in higher response rate and improved PFS over gemcitabine; a trend toward better overall survival was observed.PubMedCrossRef
9.
Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–6.PubMedCrossRef
10.
Ychou M, Conroy T, Seitz JF, et al. An open label phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/5-flourouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol. 2003;14:481–9.PubMedCrossRef
11.
Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res. 1999;5:1189–96.PubMed
12.
Ychou M, Viret F, Kramar A, et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol. 2008;62:195–201.PubMedCrossRef
13.
Conroy T, Paillot B, François E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer – a Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol. 2005;23:1228–36.PubMedCrossRef
14.
Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25:2212–7.PubMedCrossRef
15.
Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 2008;8:82.PubMedCrossRef
16.
Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–44.PubMed
17.
•• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine in patients with metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25. This pivotal randomized phase III study showed that FOLFIRINOX is superior to single-agent gemcitabine in response rate, PFS, and overall survival without a deleterious effect on quality of life.PubMedCrossRef
18.
Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509–16.PubMedCrossRef
19.
• Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 2013;31:23–9. This article presents detailed results of quality-of-life measurements in the pivotal PRODIGE 4/ACCORD 11 trial. Physical functioning, constipation, and dyspnea were dependent significant prognostic factors for survival with clinical variables.PubMedCrossRef
20.
Bendell JC, Britton S, Green MR, et al. Immediate impact of the FOLFIRINOX phase III data reported at the 2010 ASCO Annual Meeting on prescribing plans of American oncology physicians for patients with metastatic pancreas cancer. J Clin Oncol. 2011; 29 (Suppl, Abstr 286).
21.
Attard CL, Brown S, Alloul K, et al. Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer. J Clin Oncol. 2012; 30 (suppl; abstr 199).
22.
23.
Peddi PF, Lubner S, McWilliams R, et al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP. 2012;13:497–501.PubMed
24.
Vaccaro V, Bria E, Sperduti I, et al. First-line treatment with FOLFIRINOX in advanced, inoperable pancreatic cancer (APDAC) patients (pts): supportive measures optimization for a safe administration in routine clinical practice. Ann Oncol. 2012;23 Suppl 9:ix240. Abstr 721P.
25.
Goncalves PH, Ruch JM, Byer J, et al. Multi-institutional experience using 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) in patients with pancreatic cancer (PCA). J Clin Oncol. 2012; 30 (Suppl; Abstr e14519).
26.
Faris JE, Hong TS, McDermott S et al. FOLFIRINOX in locally advanced and metastatic pancreatic cancer. J Clin Oncol. 2012; 30 (Suppl 4; Abstr 313).
27.
Gunturu KS, Thumar JR, Hochster HS, et al. Single institution experience with FOLFIRINOX in advanced pancreatic cancer (PC). J Clin Oncol. 2012; 30 (Suppl 4; Abstr 330).
28.
• Hosein PJ, Macintyre J, Kawamura C, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012;12:199. This is the first published series of patients treated with FOLFIRINOX with unresectable or borderline resectable LAPC. Treatment with FOLFIRINOX in this setting is feasible and achieves some R0 resections.PubMedCrossRef
29.
Lowery MA, Yu KH, Adel NG, et al. Activity of front-line FOLFIRINOX (FFX) in stage III/IV pancreatic adenocarcinoma (PC) at Memorial Sloan-Kettering Cancer Center (MSKCC). J Clin Oncol. 2012;30:252s. Suppl; Abstr 4057.
30.
Ko AH, LoConte NK, Emily Kantoff E, et al. A phase Ib trial of FOLFIRINOX plus saridegib, an oral hedgehog (Hh) inhibitor, in pts with advanced pancreatic cancer (PDAC). J Clin Oncol. 2012; 30 (Suppl; Abstr 3105).
31.
Mahaseth H, Kauh JS, Edith Brutcher E, et al. safety and efficacy of modified FOLFIRINOX in pancreatic cancer: a retrospective experience. J Clin Oncol. 2012; 30 (Suppl; Abstr e14614).
32.
Vasile E, De Lio N, Cappelli C, et al. Neoadjuvant modified FOLFOXIRI in locally advanced pancreatic cancer. Ann Oncol. 2012;23 Suppl 9:ix241. Abstr 726P.
33.
Ginocchi L, Vasile E, Caponi S, et al. Modified FOLFOXIRI in advanced pancreatic cancer. Ann Oncol. 2012;23 Suppl 9:ix238. Abstr 714P.
34.
Assaf E, Verlindhe-Carvalho M, Delbaldo C, et al. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology. 2011;80:301–6.PubMedCrossRef
35.
Breysacher G, Kaatz O, Lemarignier C, et al. Safety and clinical effectiveness of FOLFIRINOX in metastatic pancreas cancer after first-line therapy. J Clin Oncol. 2010; 28 (Suppl; Abstr 269).
36.
Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16:1727–33.PubMedCrossRef
37.
Huguet F, André T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007;25:326–31.PubMedCrossRef
38.
Kharofa J, Kelly TR, Ritch PS, et al. 5-FU/leucovorin, irinotecan, oxaliplatin (FOLFIRINOX) induction followed by chemoXRT in borderline resectable pancreatic cancer. J Clin Oncol. 2012; 30 (Suppl; Abstr e14613).
39.
Marthey L, Sa-Cunha A, Blanc JF, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma. results of an AGEO multicentric prospective study. Ann Oncol. 2012;23 Suppl 9:ix238. Abstr 716P.
Metadata
Title
The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer
Authors
Thierry Conroy
Céline Gavoille
Emmanuelle Samalin
Marc Ychou
Michel Ducreux
Publication date
01-04-2013
Publisher
Current Science Inc.
Published in
Current Oncology Reports / Issue 2/2013
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-012-0290-4

Other articles of this Issue 2/2013

Current Oncology Reports 2/2013 Go to the issue

Evolving Therapies (RM Bukowski, Section Editor)

Tasquinimod: A Novel Angiogenesis Inhibitor–Development in Prostate Cancer

Head and Neck Cancers (EY Hanna, Section Editor)

Efficacy of Neck Dissection in the Management of Isolated Nodal Recurrence after Head and Neck Cancer Treatment

Head and Neck Cancers (EY Hanna, Section Editor)

Perineural Invasion of Head and Neck Skin Cancer: Diagnostic and Therapeutic Implications

Evolving Therapies (RM Bukowski, Section Editor)

Custirsen (OGX-011): Clusterin Inhibitor in Metastatic Prostate Cancer

Evolving Therapies (RM Bukowski, Section Editor)

Programmed Death 1 Pathway inhibition in Metastatic Renal Cell Cancer and Prostate Cancer

Head and Neck Cancers (EY Hanna, Section Editor)

Assessment of Treatment Response after Chemoradiation of Head and Neck Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits